- Home
- XRN vs EDIT Comparison
XRN vs EDIT Comparison
Compare XRN & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XRN | EDIT |
|---|---|---|
| Founded | 2011 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 481.5M | 432.8M |
| IPO Year | 2011 | 2016 |
Fundamental Metrics
Financial Performance| Metric | XRN | EDIT |
|---|---|---|
| Price | $29.19 | $2.58 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 13 |
| Target Price | ★ $38.56 | $6.10 |
| AVG Volume (30 Days) | 125.4K | ★ 2.4M |
| Earning Date | 11-04-2026 | 11-09-2026 |
| Dividend Yield | ★ 6.40% | N/A |
| EPS Growth | N/A | ★ 37.50 |
| EPS | ★ 4.73 | N/A |
| Revenue | ★ $148,208,000.00 | $31,937,000.00 |
| Revenue This Year | $4.31 | N/A |
| Revenue Next Year | $4.72 | N/A |
| P/E Ratio | $6.33 | ★ N/A |
| Revenue Growth | 6.79 | ★ 132.64 |
| 52 Week Low | $29.05 | $1.66 |
| 52 Week High | $38.65 | $3.94 |
Technical Indicators
Market Signals| Indicator | XRN | EDIT |
|---|---|---|
| Relative Strength Index (RSI) | 16.84 | 47.95 |
| Support Level | $29.05 | $2.31 |
| Resistance Level | $37.97 | $3.13 |
| Average True Range (ATR) | 0.87 | 0.20 |
| MACD | -0.43 | -0.00 |
| Stochastic Oscillator | 0.34 | 46.90 |
Price Performance
Historical ComparisonAbout XRN Chiron Real Estate Inc. Common Stock
Chiron Real Estate Inc is a real estate investment trust focused on investing and actively managing critical healthcare infrastructure. Its portfolio includes Spectrum-Dumfries, Slippery Rock MOB, Gainesville Eye Center, Aurora Sports Health, and many Others. Geographically, the company has it's concentration in a small number of states, including Texas, Florida, Ohio, Arizona, Pennsylvania, and Illinois.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.